ACCOG – Contact Details
Country
United Kingdom
Co-Chairs
Professor R. Leonard, Department of Cancer Services and Clinical Haematology, Charing Cross Hospital, 3rd Floor, North Wing, Rooms B-C, Fulham Palace Road, LONDON W6 8RF, UNITED KINGDOM. Tel: +44 20 8846 7455, Fax: +44 20 8846 7454
Dr J. Crown, St Vincent's Hospital, Elm Park, DUBLIN 4, IRELAND. Tel: +353 1 269 50 33 Fax: +353 1 269 70 49
Administration
Victoria Knox
Center
9 The Avenue, Philipstoun, By Linlithgow, West Lothian, EH49 6RE, UNITED KINGDOM. Tel: +44 1506 834320 Email: victoriaknox@angloceltic.org.uk
Website
ACCOG – Study Details
Title
Intensive chemotherapy for high-risk (>4 axillary lymph nodes) breast cancer.
Study Anglo Celtic I
Coordinator(s)
Professor R. Leonard, Department of Cancer Services and Clinical Haematology, Charing Cross Hospital, 3rd Floor, North Wing, Rooms B-C, Fulham Palace Road, LONDON W6 8RF, UNITED KINGDOM. Tel: +44 20 8846 7455 Fax: +44 20 8846 7454
J. Crown, St Vincent's Hospital, Elm Park, DUBLIN 4, IRELAND. Tel: +353 1 269 50 33 Fax: +353 1 269 70 49 Email: John.Crown@icorg.ie
Summary
- Closed in June 1999 (opened in February 1995)
- Target accrual: 600 patients
Objective
- To determine the comparative efficacy of a high-dose sequential chemotherapy programme versus conventional CMF following doxorubicin induction in patients with high-risk primary breast cancer.
Scheme
Update
- Study closed in June 1999.
- 605 patients entered.
- Early results were presented by poster at ASCO 2002.
Related Publications
Conventional adjuvant chemotherapy versus single-cycle, autograft- supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Nat Cancer Inst 2004; 96(14): 1076–1083.
Topics
- High-dose chemotherapy
- Node positive breast cancer
Keywords
Breast cancer, high-dose chemotherapy
***************************************************
Title
A randomised comparative trial of Adriamycin and Taxotere versus Adriamycin and Cyclophosphamide as primary therapy for patients with potentially operable disease >3cm diameter, locally advanced or inflammatory breast cancer.
Study Anglo Celtic II
Coordinator(s)
J. Mansi, Oncology, St George's Hospital, Blackshaw Road, LONDON SW17 0Q, UNITED KINGDOM. Tel: +44 (0)20 8725 2955 Fax: +44 (0)20 8725 1199
J. Evans, Beatson Oncology Center, Western Infirmary, Dumbarton Road, GLASGOW G11 6NT, UNITED KINGDOM. Tel: +44 (0)141 211 1741 Fax: +44 (0)141 211 1830
Summary
- Opened in October 1998
- Target accrual: 350 patients
Objective
- To compare the efficacy (response rates) and toxicity of Adriamycin and Taxotere versus Adriamycin and Cyclophosphamide as primary medical therapy regimens in early breast cancer.
Scheme
Update
- Study closed 2001.
- 363 patients entered.
- Early results were presented by poster at ASCO 2002.
Related Publications
Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005; 23(13): 2988–2995.
Topics
- Taxanes
- Anthracyclines
Keywords
Primary medical therapy, breast cancer
***************************************************
Title
Prospective randomized comparison of G-CSF (filgrastim) secondary prophylaxis versus conservative management of chemotherapy-induced neutropenia to maintain dose intensity in chemotherapy for breast cancer.
Study Anglo Celtic III
Coordinator(s)
Professor R. Leonard, Department of Cancer Services and Clinical Haematology, Charing Cross Hospital, 3rd Floor, North Wing, Rooms B-C, Fulham Palace Road, LONDON W6 8RF, UNITED KINGDOM. Tel: +44 20 8846 7455 Fax: +44 20 8846 7454
Summary
- Opened in October 2001
- Target accrual: 400 patients
Objective
- To compare the effects of G-CSF secondary prophylaxis against standard management after the first neutropenic event in achieving planned dose intensity of chemotherapy for early breast cancer.
Scheme
Update
- Recruitment target reduced to 400; 367 patients recruited to date.
Related Publications
None available
Topics
- GCSF secondary prophylaxis
Keywords
Early breast cancer, dose intensity
***************************************************
Title
A randomized 2-arm, prospective, multi-centre, open label phase III trial comparing the activity and safety of a weekly versus a 3-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer.
Study Anglo Celtic IV
“Will Weekly Win”, www.taxol-uk.com
Coordinator(s)
Dr M. Verrill, University of Newcastle Department of Oncology, Newcastle General Hospital, Westgate Road, NEWCASTLE-UPON-TYNE, NE4 6BE, UNITED KINGDOM. Tel: +44 (0)191 219 4252 Fax: +44 (0)191 273 4867 Email: mark.verrill@ncl.ac.uk
Dr D. Cameron, NCRN Coordinating Centre, Arthington House, Cookridge Hospital, Hospital Lane, LEEDS LS16 6QB, UNITED KINGDOM. Tel: +44 (0)113 3924093 Fax: +44 (0)113 3924092 Email: d.cameron@ncrn.org.uk
Summary
- Opened in September 2002
- Target accrual: 600 patients
Primary Objectives
- To compare the antitumour efficacy of weekly versus 3-weekly paclitaxel as determined by the time to disease progression.
- To study polymorphisms in the genes responsible for paclitaxel metabolism and link these to response rates and toxicity.
Secondary Objectives
- To compare the toxicity of weekly versus 3-weekly paclitaxel.
- To compare the response rate of weekly versus 3-weekly paclitaxel.
- To compare overall survival in patients receiving weekly versus 3-weekly paclitaxel.
- To compare quality of life in patients receiving weekly versus 3-weekly paclitaxel.
Scheme
Update
- 569 patients have been randomized from 55 active centres.
- Early results willl be presented at NCRI 2006.
Related Publications
None available
Topics
- Metastatic breast cancer
- Taxanes
Keywords
Chemotherapy scheduling
***************************************************
Title
Ovarian protection trial in oestrogen non-responsive premenopausal breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy.
Anglo Celtic V – OPTION
Coordinator(s)
Professor R. Leonard, Department of Cancer Services and Clinical Haematology, Charing Cross Hospital, 3rd Floor, North Wing, Rooms B-C, Fulham Palace Road, LONDON W6 8RF, UNITED KINGDOM. Tel: +44 20 8846 7455 Fax: +44 20 8846 7454
Summary
- A study to assess the value of goserelin ovarian suppression in the prevention of chemotherapy-associated menopause in premenopausal women with early or locally advanced breast cancer.
Scheme
Update
- Over 70 centres in the UK open for recruitment; 67 patients recruited to date.
Related Publications:
None available
Topics
- Premenopausal patients
- Fertility and chemotherapy
Keywords
Early breast cancer, ovarian protection
